These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 17138126

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.
    Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ.
    J Urol; 2004 Sep; 172(3):910-4. PubMed ID: 15310996
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H.
    J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
    Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H.
    J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML.
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [Abstract] [Full Text] [Related]

  • 13. Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer.
    Krygiel JM, Smith DS, Homan SM, Sumner W, Nease RF, Brownson RC, Catalona WJ.
    J Urol; 2005 Jul; 174(1):126-30. PubMed ID: 15947596
    [Abstract] [Full Text] [Related]

  • 14. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.
    Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ.
    Urology; 2005 Jul; 66(1):156-60. PubMed ID: 15992903
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML.
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [Abstract] [Full Text] [Related]

  • 17. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
    Freedland SJ, Partin AW, Epstein JI, Walsh PC.
    Cancer; 2004 Apr 15; 100(8):1646-9. PubMed ID: 15073852
    [Abstract] [Full Text] [Related]

  • 18. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF, Abdel-Aziz KF, Roehrborn CG, Lotan Y.
    Eur Urol; 2006 Feb 15; 49(2):293-302. PubMed ID: 16387412
    [Abstract] [Full Text] [Related]

  • 19. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
    Jang TL, Han M, Roehl KA, Hawkins SA, Catalona WJ.
    Urology; 2006 Feb 15; 67(2):343-8. PubMed ID: 16442594
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.